US drug major Wyeth's first quarter profit was unchanged year-on-year, as the firm prepared to be acquired by global drug giant Pfizer (Marketletters passim).
The firm's net income was flat at $1.2 billion, or $0.90 per share, while R&D expenses were down 8% to $773.1 million as the company cut costs ahead of its merger.
Group turnover decreased 6% to $5.38 billion, with nutritional products contributing $415.0 million to the total, an increase of 1%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze